Apyx Medical (Apyx Medical) Cash, Cash Equivalents, Marketable Securities : $37.28 Mil (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Cash, Cash Equivalents, Marketable Securities?

Apyx Medical's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($22.13 Mil) to Dec. 2023 ($43.65 Mil) but then stayed the same from Dec. 2023 ($43.65 Mil) to Mar. 2024 ($37.28 Mil).

Apyx Medical's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($30.87 Mil) to Dec. 2022 ($10.19 Mil) but then increased from Dec. 2022 ($10.19 Mil) to Dec. 2023 ($43.65 Mil).

Apyx Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Apyx Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Cash, Cash Equivalents, Marketable Securities Chart

Apyx Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

58.81

41.92

30.87

10.19

43.65

Apyx Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															16.26	18.48	22.13	43.65	37.28

Apyx Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Apyx Medical (NAS:APYX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Apyx Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Apyx Medical (Apyx Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

BOV:Germany

Address

5115 Ulmerton Road, Clearwater, FL, USA, 33760

Website

https://apyxmedical.com

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Executives

Todd Hornsby	officer: Executive Vice President	14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine	director	75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb	officer: Chief Financial Officer	5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal	director	5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty	director	1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman	director	5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres	director	86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers	officer: Chief Financial Officer	4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron	director, officer: President
Robert Gershon	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii	officer: Chief CommercializationOfficer	23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson	director	C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz	officer: Vice President of Operations